Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at a double-digit premium as the biotech pares expenses.

Verastem Oncology Inc. (NASDAQ:VSTM) has identified as a key priority its combination of newly acquired MEK and RAF inhibitor VS-6766 plus FAK inhibitor defactinib to treat K-Ras mutant solid tumors, including low-grade serous ovarian cancer, non-small cell lung cancer (NSCLC) and colorectal cancer...